As shown in Table 6, no correlation was found between mTOR overexpression and any clinicopathological parameters, such as differentiation (OR = 1.59, 95%CI: 0.33–07.57, P = 0.56), depth of invasion (OR = 0.88, 95%CI: 0.59–1.31, P = 0.54), lymph node metastasis (OR = 1.72, 95%CI: 0.98–3.01, P = 0.06) or TNM stage (OR = 3.13, 95%CI: 0.72–13.61, P = 0.13). The gene discussed is MTOR; the disease is metastatic malignant neoplasm in the lymph nodes.